Perrigo launches new generic version of Axiron topical solution

Perrigo has announced the launch of a new generic prescription pharmaceutical product for the treatment of testosterone deficiencies.

The testosterone topical solution is based on Axiron, a branded product from Lilly that is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Annual market sales of Axiron for the 12 months ending April 2017 came to approximately $248 million (191.27 million pounds), demonstrating the commercial opportunity that this new generic launch represents.

This marks Perrigo's third new product launch in the last two weeks and underlines the firm's commitment to broadening its range of complex topical products, with more than five new prescription products to be introduced in this category by the end of 2017.

John Wesolowski, Perrigo's executive vice-president and president for prescription pharmaceuticals, said: "These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.